[144] Progyny, Inc. SEC Filing
This article details a Form 144 SEC filing by Progyny, Inc. (PGNY) on May 22, 2026, indicating a proposed sale of 2,676 shares of common stock with an aggregate market value of $66,177.48. The securities were acquired through restricted stock vesting as compensation.
Progyny Inc Annual Shareholders Meeting Transcript
This article provides a transcript from Progyny Inc.'s Annual Shareholders Meeting held on May 21, 2026, at 07:00 PM GMT. The content includes a partial transcript of welcoming remarks and instructions for attendees to hold the line, indicating the start of the meeting. It also lists various past earnings calls and conference transcripts for Progyny Inc.
Progyny CFO Mark S. Livingston sells $211,012 of common stock
Progyny's CFO, Mark S. Livingston, sold 8,275 shares of the company's common stock for $211,012 on May 20, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, Livingston still holds a significant number of shares, and the company has shown strong financial performance, exceeding Q1 expectations and receiving positive analyst upgrades.
Progyny (PGNY) CFO sells 8,275 shares under Rule 10b5-1 plan
Progyny, Inc. CFO Mark S. Livingston sold 8,275 shares of common stock at $25.50 per share on May 20, 2026, as part of a pre-arranged Rule 10b5-1 trading plan established on August 15, 2025. Following this transaction, Livingston directly holds 79,063 shares of Progyny. The sale, valued at $211,013, was an open-market transaction.
Progyny (PGNY) COO Melissa Cummings sells 9,578 shares under 10b5-1 plan
Progyny (PGNY) Chief Operating Officer Melissa B. Cummings sold 9,578 shares of common stock at $25.00 per share on May 19, 2026. This transaction was executed as an open-market sale under a pre-arranged Rule 10b5-1 trading plan established on December 19, 2025. Following the sale, Cummings directly holds 73,371 shares of Progyny common stock.
Progyny Inc (PGNY) Stock Down 3.8% -- Now Undervalued? GF Score: 87/100
Progyny Inc (PGNY) saw its stock decline by 3.8% to $24.69, yet GuruFocus assesses it as "Modestly Undervalued" with a GF Value™ of $27.78 and a strong GF Score™ of 87/100. Despite positive financial strength, profitability, and growth ratings, the company faces low momentum (2/10) and recent insider selling, which investors should consider. Its current P/E ratio of 32.1x is significantly below its historical median, suggesting an attractive valuation.
Transcript : Progyny, Inc. - Shareholder/Analyst Call
This article provides a transcript from a shareholder/analyst call for Progyny, Inc. The call was led by CEO Peter Anevski, but the full content is reserved for subscribers. The article also includes recent news, analyst ratings, and financial data about Progyny, Inc.
Notice of proposed sale for PGNY (NASDAQ: PGNY) with recent RSU vesting
A Form 144 filing for Progyny, Inc. (NASDAQ: PGNY) indicates a proposed sale of common stock under Rule 144 and details recent restricted stock unit (RSU) vesting events. The filing, associated with Fidelity Brokerage Services LLC, lists vesting on March 2, 3, and 4, 2026, for 256, 7,420, and 599 shares respectively. These events are relevant to investors as they can impact share supply and price, as well as signal insider intent.
CCORF Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $30
CCORF has reiterated its Buy rating for Progyny (PGNY.US), while simultaneously maintaining its target price of $30. This indicates a continued positive outlook from the firm regarding Progyny's stock performance.
Canaccord Genuity Upgrades Progyny to Buy From Hold, Adjusts PT to $30 From $19
Canaccord Genuity has upgraded Progyny (PGNY) to "Buy" from "Hold" and increased its price target to $30 from $19. This adjustment reflects a positive outlook on the managed healthcare company. Progyny specializes in fertility and family building benefits solutions, serving approximately 6.7 million employees and partners through its Smart Cycle approach and Progyny Rx.
Progyny (PGNY) Stock Is Up, What You Need To Know
Shares of fertility benefits company Progyny (PGNY) rose after Canaccord Genuity upgraded the stock to Buy with a raised price target of $30, citing six consecutive quarters of exceeding revenue and adjusted EBITDA estimates. Canaccord also anticipates a return to double-digit revenue growth in the second half of 2026. This follows a previous 17.5% jump in the stock after Progyny reported strong Q1 2026 results and raised its full-year guidance.
[144] Progyny, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Progyny, Inc. (PGNY) detailing a proposed sale of securities. The filing indicates a neutral impact and sentiment, outlining the filer and issuer information, the securities to be sold (9,578 shares of common stock acquired through restricted stock vesting), and confirming no prior sales in the last three months.
Canaccord upgrades Progyny stock rating to buy on guidance beat streak
Canaccord Genuity upgraded Progyny (NASDAQ: PGNY) shares from Hold to Buy and raised its price target to $30 from $19, citing the company's consistent beat of quarterly revenue and adjusted EBITDA estimates for six consecutive quarters. Progyny is currently trading at $24.05, with InvestingPro suggesting it is undervalued with a Fair Value of $31.53. The firm anticipates Progyny will return to double-digit revenue growth in the second half of 2026 and expects its trend of meeting expectations, double-digit growth (excluding Amazon impact), and robust free cash flow to continue.
Canaccord Genuity Upgrades Progyny to Buy From Hold, Adjusts PT to $30 From $19
Canaccord Genuity has upgraded Progyny (PGNY) from a "Hold" to a "Buy" rating. The firm also increased its price target for Progyny shares to $30 from $19. This upgrade suggests a more optimistic outlook on the company's future performance by Canaccord Genuity.
Canaccord upgrades Progyny stock rating to buy on guidance beat streak
Canaccord Genuity has upgraded Progyny (NASDAQ:PGNY) shares from Hold to Buy and increased its price target to $30 from $19. The upgrade follows Progyny's consistent outperformance of quarterly revenue and adjusted EBITDA estimates for six consecutive quarters, attributed to a conservative guidance approach. Analysts anticipate double-digit revenue growth in the second half of 2026, despite potential near-term volatility, and note the company's strong free cash flow and aggressive share repurchase program.
Responsive Playbooks and the PGNY Inflection
This article analyzes Progyny Inc. (NASDAQ: PGNY) using AI models to provide trading strategies and risk management parameters. It identifies a strong near and mid-term sentiment, tests resistance, and presents specific entry, target, and stop-loss levels for long, breakout, and short positions. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
US proposes rule for employer-sponsored fertility benefits
The US government has proposed a new rule that would require employer-sponsored health plans to cover fertility benefits. This initiative aims to expand access to fertility treatments for more individuals and couples. The proposed rule reflects a growing recognition of the importance of reproductive health in employer benefits.
The Strong Earnings Posted By Progyny (NASDAQ:PGNY) Are A Good Indication Of The Strength Of The Business
Progyny (NASDAQ:PGNY) recently reported strong earnings, which the market received positively. The article highlights that Progyny's accrual ratio of -0.55 indicates its statutory earnings were significantly less than its free cash flow, suggesting strong underlying earnings potential. Analysts are forecasting continued profitability for the company, further bolstering confidence in its financial health.
Progyny stock (US74340E1038): fertility benefits specialist back in focus after strong quarterly upd
Progyny Inc. (PGNY), a leading US provider of fertility and family-building benefits, has garnered renewed attention after its latest quarterly results highlighted continued revenue growth and strong demand from corporate clients. The company specializes in designing and managing benefit programs, integrating medical and pharmacy services for large employers to offer competitive reproductive health options to their workforce. This positions Progyny at the intersection of healthcare, employee benefits, and demographic changes, making it a noteworthy stock for US investors tracking trends in employer-sponsored healthcare and evolving family-building attitudes.
Progyny stock (US74340E1038): fertility benefits specialist back in focus after latest business upda
Progyny, a US-based fertility benefits provider, is gaining attention again after its latest business update highlighted sustained revenue growth and strong demand for employer-sponsored reproductive health plans. The company's core model focuses on integrated fertility and family-building benefits for large self-insured employers, aiming to improve outcomes and manage costs. Key revenue drivers include increasing employer contracts, utilization of fertility treatments, and associated pharmacy services, though the company is sensitive to economic shifts and corporate benefit budget changes.
Shareholders Will Be Pleased With The Quality of Progyny's (NASDAQ:PGNY) Earnings
Progyny's Q1 earnings report was well-received by investors, with the company demonstrating strong conversion of profit to free cash flow. A negative accrual ratio of -0.55 indicates that Progyny's free cash flow significantly exceeded its statutory profit, suggesting its underlying earnings potential is better than initially appears. This positive financial indicator, combined with impressive earnings per share growth over the last three years, bodes well for the company's future profitability.
The Strong Earnings Posted By Progyny (NASDAQ:PGNY) Are A Good Indication Of The Strength Of The Business
Progyny (NASDAQ:PGNY) recently announced strong earnings, which the market received positively. The company's accrual ratio of -0.55 indicates that its free cash flow significantly exceeded its reported profit, suggesting a strong underlying earnings potential. Progyny's earnings per share have also shown impressive growth over the past three years.
Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
Progyny (PGNY) reported Q1 earnings of $0.5 per share, exceeding the Zacks Consensus Estimate of $0.44, and revenues of $328.5 million, surpassing the estimate by 0.29%. The company has consistently beaten EPS and revenue estimates over the last four quarters. Despite the positive earnings, Progyny's shares have declined by 27.2% year-to-date, contrasting with the S&P 500's gain.
Progyny, Inc. $PGNY Shares Bought by First Eagle Investment Management LLC
First Eagle Investment Management LLC significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 40.2% in the fourth quarter of the prior year, bringing its total holdings to $5.46 million worth of shares. Other institutional investors also boosted their positions, with 94.93% of Progyny's stock now owned by hedge funds and institutions. The company reported strong Q1 earnings, beating analyst expectations with an EPS of $0.29 against an estimated $0.26, and analysts maintain a "Moderate Buy" consensus with an average price target of $28.18.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Progyny, Inc. announced that its CEO, Pete Anevski, and CFO, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference. The event is scheduled for Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time. A live audiocast and replay will be available on Progyny's investor relations website for those interested in listening.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Progyny, Inc. announced that its CEO, Pete Anevski, and CFO, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference. The event is scheduled for Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time. The company, a leader in women's health and family building solutions, also noted its stock's presence in various ChartMill screener lists, including "High Free Cash Flow Stocks" and "GARP Stocks."
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Progyny, Inc. announced that its CEO, Pete Anevski, and CFO, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026. The event will be audiocast live and available for replay on Progyny's investor website. Progyny is a global leader in women’s health and family building solutions, recognized for its comprehensive and inclusive approach that benefits employers, patients, and physicians.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Progyny, Inc. is scheduled to present at the BofA Securities 2026 Health Care Conference. The exact time of the company's presentation has not yet been announced. This news was published on May 11, 2026.
Women’s health company Progyny to speak at BofA 2026 conference
Progyny (Nasdaq: PGNY) announced that its CEO Pete Anevski and CFO Mark Livingston will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026. The session will be held at 11:20 a.m. PT / 2:20 p.m. ET, with a live audiocast and replay available on Progyny’s investor relations website. This presentation follows a period of mixed market reactions to recent company news, including product launches and earnings reports.
Citizens raises Progyny stock price target on higher EBITDA outlook
Citizens has increased its price target on Progyny (NASDAQ:PGNY) stock to $31 from $30, maintaining a Market Outperform rating. This update is based on a higher 2026 EBITDA estimate of $239 million and the company's strong financial health and growth prospects for new products. Progyny also reported better-than-expected Q1 results, with adjusted EPS of $0.50 and record revenue of $328.5 million.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Progyny, Inc. announced that its CEO, Pete Anevski, and CFO, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference. The event is scheduled for Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time. A live audiocast and replay will be available on Progyny's investor relations website.
Progyny, Inc. 1Q 2026: Revenue $328.5M, EPS $0.29— 10-Q Summary
Progyny, Inc. reported its first-quarter 2026 results, showing a slight increase in revenue to $328.5 million and a significant rise in net income to $24.23 million, leading to diluted EPS of $0.29. The company saw growth in membership and improvements in gross margin, despite a minor decline in assisted reproductive technology cycles. Progyny also focused on diversification through new industry additions, expanded women's health offerings, and completed a share repurchase program.
Progyny, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PGNY)
Progyny, Inc. (NASDAQ:PGNY) released its Q1 2026 earnings, reporting an EPS of $0.50, which beat estimates by $0.06, and revenue of $328.50M, exceeding expectations by $1.99M with a 1.38% year-over-year increase. The company published a slide deck in conjunction with its earnings call.
Fertility benefits growth and share buybacks keep Progyny (PGNY) earnings in focus
NULL
Progyny (PGNY) boosts Q1 2026 profit as margins expand and buybacks surge
Progyny (PGNY) reported a significant increase in Q1 2026 net income to $24.2 million from $15.1 million in Q1 2025, driven by expanding gross margins and lower operating costs despite modest 1% revenue growth. The company's gross margin improved to 25.3%, supported by care management efficiencies and reduced stock-based compensation. Progyny also completed a $200 million share repurchase program, buying back 5.5 million shares, which contributed to an increase in diluted EPS to $0.29.
Progyny, Inc. Announces First Quarter 2026 Results - The Globe and Mail
Progyny, Inc. announced strong financial results for the first quarter of 2026, reporting a record revenue of $328.5 million, a 1.4% increase year-over-year. The company highlighted robust demand for women's health and family building solutions, with member engagement trending towards the higher end of expectations. Progyny also returned value to shareholders by repurchasing 8.8 million shares since November, and provided financial guidance for the second quarter and full year 2026, projecting continued revenue and adjusted EBITDA growth.
Progyny Delivers Record Q1 2026 Revenue and Growth
Progyny reported record Q1 2026 revenue of $328.5 million, marking growth in fertility and pharmacy benefit services despite losing a large client. Net income rose while adjusted EBITDA slightly decreased due to investment in platform enhancements. The company also completed a $200 million share repurchase program, reflecting strong demand for its services and a robust financial position.
GUIDANCE: (PGNY) Progyny, Inc. Expects Q2 Revenue Range $342.0M - $355.0M
Progyny, Inc. (PGNY) announced its Q2 revenue guidance, expecting it to fall between $342.0 million and $355.0 million. This financial outlook provides investors with an anticipated snapshot of the company's performance for the upcoming quarter.
(PGNY) Progyny, Inc. Expects Q2 Revenue Range $342.0M - $355.0M
Progyny, Inc. (PGNY) anticipates its Q2 revenue to fall between $342.0 million and $355.0 million. The company, a benefit management specialist in fertility and family building solutions, provides services through its Smart Cycle approach. Progyny also offers an integrated pharmacy benefits solution, Progyny Rx, and has approximately 6.4 million employees and their partners covered by its services.
Record Q1 revenue and major buybacks at Progyny (NASDAQ: PGNY) shape 2026 outlook
Progyny (NASDAQ: PGNY) reported record Q1 2026 revenue of $328.5 million and net income of $24.2 million, demonstrating underlying growth despite the loss of a large client. The company completed its $200 million share repurchase program, buying back 8.8 million shares, and maintains a strong balance sheet with $225.1 million in cash and no debt. Progyny also provided a positive full-year 2026 outlook, projecting revenue between $1.365 billion and $1.405 billion, and Adjusted EBITDA of $232.0 million to $244.0 million.
Progyny earnings in the spotlight as fertility market heats up
Progyny Inc. is set to release its first-quarter earnings, with analysts expecting $0.26 per share on revenue of $326.6 million, reflecting growth in a rapidly expanding fertility benefits market. Investors will be closely watching the sustainability of revenue growth and uptake of its new Progyny Select offering, as the company aims to capitalize on increasing employer demand for fertility and family-building benefits. The company is navigating seasonal challenges while seeking to build on a strong prior quarter.
Progyny, Inc. Announces First Quarter 2026 Results
Progyny, Inc. reported strong first-quarter 2026 results with record revenue of $328.5 million, an increase of 1.4% from the prior year, despite the exit of a large client. The company highlighted robust demand for women's health and family building solutions, driven by macro trends of deferred family building. Progyny also announced the completion of its $200 million share repurchase program, having bought back 8.8 million shares, and provided financial guidance for the second quarter and full year 2026, projecting continued revenue and earnings growth.
Number of shareholders of Progyny, Inc. – BX:PGNY
The article focuses on the number of shareholders for Progyny, Inc. (BX:PGNY) and appears to be a stub or a section of a larger financial data page. It indicates that specific shareholder figures would be displayed based on the selected period and value.
Is Progyny (PGNY) Pricing Reflect Its DCF Upside After Recent Share Price Rebound
This article analyzes Progyny (PGNY) using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio models to assess its current valuation. The DCF model suggests PGNY is significantly undervalued by 72.7% with an intrinsic value of $69.52 per share compared to its current price of $18.98. The P/E ratio analysis also indicates Progyny is slightly undervalued relative to its fair ratio and peers, despite recent short-term share price fluctuations.
Progyny Q1 2026 Earnings Preview — May 7, Street Expects $0.44 EPS
Progyny, Inc. is set to announce its Q1 2026 earnings on May 7, with analysts forecasting earnings of $0.44 per share on revenue of $326.5 million. While EPS shows a significant year-over-year increase of 158.8% from $0.17, revenue growth is projected to be a modest 0.8%, indicating substantial margin improvement. Investors should closely monitor client count, member utilization rates, and management's guidance for the rest of 2026 to assess the company's profitability trajectory and sustainability.
Earnings Preview: Progyny to Report Financial Results Post-market on May 07
Progyny is scheduled to report its financial results post-market on May 7th. The market will be watching closely to see if the company announces a surprise earnings beat or miss, as well as if any new guidance is provided. Investors often react significantly to these announcements.
Universal Beteiligungs und Servicegesellschaft mbH Acquires 70,021 Shares of Progyny, Inc. $PGNY
Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 92.6%, acquiring an additional 70,021 shares to own 145,647 shares in total, valued at approximately $3.75 million. Progyny has an average analyst rating of "Moderate Buy" with a $27.91 price target, while the stock trades near $18.42. The company recently exceeded quarterly earnings expectations and provided positive guidance for FY2026 and Q1 2026.
Vanguard Portfolio Management Boosts PGNY Stake to 6.54% (PGNY)
Vanguard Portfolio Management has increased its passive stake in Progyny Inc. (PGNY) to 6.54%, beneficially owning 5,357,311 shares as of March 31, 2026. This information comes from a Schedule 13G SEC filing, indicating that Vanguard holds these shares through various funds and managed accounts, primarily for investment purposes rather than control. The filing also specifies Vanguard's sole voting power over 65,283 shares and sole dispositive power over all 5,357,311 shares.
Will Progyny Select’s Small-Employer Fertility Launch Redefine Progyny's (PGNY) Risk-Pooling Narrative?
Progyny (PGNY) recently launched "Progyny Select," a fully insured supplemental fertility and family-building plan aimed at small U.S. employers for the 2027 plan year. This new offering, which packages their managed network and care advocates into a pooled-risk model, aims to broaden their client base beyond large corporations. While the initiative demonstrates management's confidence and expands market access, its near-term impact depends on broker adoption and faces potential risks from employer cost-cutting, alongside Progyny's ongoing share repurchase program.
Will Progyny Select’s Small-Employer Fertility Launch Redefine Progyny's (PGNY) Risk-Pooling Narrative?
Progyny, Inc. recently introduced Progyny Select, a fully insured fertility and family-building plan aimed at small U.S. employers for the 2027 plan year. This new offering extends their services to a broader market through a pooled-risk model, addressing financial and structural barriers to fertility and women’s health support. The initiative, alongside a significant share repurchase program, signals management's confidence and an effort to expand their client base beyond large corporations, though market adoption and cost controls remain key factors for investors to consider.
